Use of animal models to develop antiaddiction medications

Current Psychiatry Reports

Volumn 10, Issue 5, 2008, Pages 377-384

  Gardner, Eliot L ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; BACLOFEN; DOPAMINE; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE TRANSPORTER; DOPAMINE TRANSPORTER BLOCKING AGENT; DRUGS USED IN THE TREATMENT OF ADDICTION; DYNORPHIN; ENDORPHIN; ENKEPHALIN; GLUTAMIC ACID; N [4 [2 (6 CYANO 1,2,3,4 TETRAHYDRO 2 ISOQUINOLINYL)ETHYL]CYCLOHEXYL] 4 QUINOLINECARBOXAMIDE; NGB 2904; PROTEIN INHIBITOR; SEROTONIN; UNCLASSIFIED DRUG; VIGABATRIN;

ALCOHOLISM; ANIMAL BEHAVIOR; BRAIN DEPTH STIMULATION; BRAIN REGION; COCAINE DEPENDENCE; DISEASE MODEL; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG DEPENDENCE; DRUG MECHANISM; DRUG RESEARCH; DRUG SELECTIVITY; DRUG SELF ADMINISTRATION; DYSPHORIA; EUPHORIA; GABAERGIC SYSTEM; HEROIN DEPENDENCE; HUMAN; MICRODIALYSIS; NONHUMAN; PATHOPHYSIOLOGY; PLACE PREFERENCE; POTENTIOMETRY; REINFORCEMENT; RELAPSE; REVIEW; REWARD; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

ANIMALS; BRAIN; CONDITIONING, CLASSICAL; DISEASE MODELS, ANIMAL; DOPAMINE ANTAGONISTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; GABA AGONISTS; HUMANS; MOTIVATION; NERVE NET; NEUROTRANSMITTER AGENTS; RECEPTORS, DOPAMINE D3; RECEPTORS, GABA-B; RECURRENCE; SUBSTANCE-RELATED DISORDERS;

EID: 58649111693     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-008-0061-y     Document Type: Review

References (50)

1. O'Brien CP: Drug addiction and drug abuse. In Goodman & Gilman's The Pharmacological Basis of Therapeutics, edn 11. Edited by Brunton L, Lazo J, Parker K. New York: McGraw-Hill; 2005: 607-628.
2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, edn 4 (text revision). Washington, DC: American Psychiatric Association; 2000.
3. Volkow ND,TLi TK: Drug addiction: the neurobiology of behavior gone awry. Nat Rev Neurosci 2004, 5: 963-970.
4. Di Chiara G: Drug addiction as dopamine-dependent associative learning disorder. Eur J Pharmacol 1999, 375: 13-30.
5. Gardner EL: Brain reward mechanisms. In Substance Abuse: A Comprehensive Textbook, edn 4. Edited by Lowinson JH, Ruiz P, Millman RB, Langrod JG. Philadelphia: Lippincott Williams & Wilkins; 2005: 48-97.
6. Gallistel CR, Shizgal P, Yeomans JS: A portrait of the substrate for self-stimulation. Psychol Rev 1981, 88: 228-273.
7. Pontieri FE, Tanda G, Di Chiara G: Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the "shell" as compared with the "core" of the rat nucleus accumbens. Proc Natl Acad Sci U S A 1995, 92: 12304-12308.
8. Shalev U, Grimm JW, Shaham Y: Neurobiology of relapse to heroin and cocaine seeking: A review. Pharmacol Rev 2002, 54: 1-42.
9. Wilson SJ, Sayette MA, Fiez JA: Prefrontal responses to drug cues: a neurocognitive analysis. Nat Neurosci 2004, 7: 211-214.
10. Garavan H, Pankiewicz J, Bloom A, et al.: Cue-induced cocaine craving: neuroanatomical specificity for drug users and drug stimuli. Am J Psychiatry 2000, 157: 1789-1798.
11. Risinger RC, Salmeron BJ, Ross TJ, et al.: Neural correlates of high and craving during cocaine self-administration using BOLD fMRI. Neuroimage 2005, 15: 1097-1108.
12. Gardner EL, Chen J, Paredes W: Overview of chemical sampling techniques. J Neurosci Methods 1993, 48: 173-197.
13. Tzschentke TM: Measuring reward with the conditioned place preference paradigm: A comprehensive review of drug effects, recent progress and new issues. Prog Neurobiol 1998, 56: 613-672.
14. Tzschentke TM: Measuring reward with the conditioned place preference (CPP) paradigm: Update of the last decade. Addict Biol 2007, 12: 227-462.
15. Panlilio LV, Goldberg SR: Self-administration of drugs in animals and humans as a model and an investigative tool. Addiction 2007, 102: 1863-1870.
16. Richardson NR, Roberts DCS: Progressive ratio schedules in drug self-administration studies in rats: A method to evaluate reinforcing efficacy. J Neurosci Methods 1996, 66: 1-11.
17. Gardner EL: What we have learned about addiction from animal models of drug self-administration. Am J Addict 2000, 9: 285-313.
18. Everitt BJ, Robbins TW: Second-order schedules of drug reinforcement in rats and monkeys: Measurement of reinforcing efficacy and drug-seeking behaviour. Psychopharmacology 2000, 153: 17-30.
19. Goldberg SR, Tang AH: Behavior maintained under second-order schedules of intravenous morphine injection in squirrel and rhesus monkeys. Psychopharmacology 1977, 51: 235-242.
20. Shaham Y, Shalev U, Lu L, et al.: The reinstatement model of drug relapse: History, methodology and major findings. Psychopharmacology 2003, 168: 3-20.
21. Epstein DH, Preston KL, Stewart J, Shaham Y: Toward a model of drug relapse: An assessment of the validity of the reinstatement procedure. Psychopharmacology 2006, 189: 1-16.
22. Tims FM, Leukefeld CG, Platt JJ, eds: Relapse and Recovery in Addictions. New Haven, CT: Yale University Press; 2001.
23. Shalev U, Grimm JW, Shaham Y: Neurobiology of relapse to heroin and cocaine seeking: A review. Pharmacol Rev 2002, 54: 1-42.
24. Cooper A, Barnea-Ygael N, Levy D, et al.: A conflict rat model of cue-induced relapse to cocaine seeking. Psychopharmacology 2007, 194: 117-125.
25. Lu L, Xu N-J, Ge X, et al.: Reactivation of morphine conditioned place preference by drug-priming: A role of environmental cues and sensitization. Psychopharmacology 2002, 159: 125-132.
26. Lu L, Zhang B, Liu Z, Zhang Z: Reactivation of cocaine conditioned place preference induced by stress is reversed by cholecystokinin-B receptors antagonist in rats. Brain Res 2002, 954: 132-140.
27. Ribeiro Do Couto B, Aguilar MA, Manzanedo C, et al.: Social stress is as effective as physical stress in reinstating morphine-induced place preference in mice. Psychopharmacology 2006, 185: 459-470.
28. Kreibich AS, Blendy JA: CAMP response element-binding protein is required for stress but not cocaine-induced reinstatement. J Neurosci 2004, 24: 6686-6692.
29. Lu L, Chen H, Su W, et al.: Role of withdrawal in reinstatement of morphine-conditioned place preference. Psychopharmacology 2005, 181: 90-100.
30. Sanchez CJ, Sorg BA: Conditioned fear stimuli reinstate cocaine-induced conditioned place preference. Brain Res 2001, 908: 86-92.
31. Ettenberg A: Opponent process properties of self-administered cocaine. Neurosci Biobehav Rev 2004, 27: 721-728.
32. Gardner EL: The neurobiology and genetIcs of addiction: implications of the "reward deficiency syndrome" for therapeutic strategies in chemical dependency. In Addiction: Entries and Exits. Edited by Elster J. New York: Russell Sage; 1999: 57-119.
33. Volkow ND, Ding Y-S, Fowler JS, et al.: Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 1995, 52: 456-463.
34. Froimowitz M, Wu K-M, Moussa A, et al.: Slow-onset, long-duration 3-(3′,4′-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse. J Med Chem 2000, 43: 4981-4992.
35. Gardner EL, Liu X, Paredes W, et al.: A slow-onset, long-duration indanamine monoamine reuptake inhibitor as a potential maintenance pharmacotherapy for psycho-stimulant abuse: Effects in laboratory rat models relating to addiction. Neuropharmacology 2006, 51: 993-1003.
36. Peng XQ, Xi ZX, Gilbert JG, et al.: Behavioral and neurochemical effects of CTDP-31,345, a novel slow-onset and long-duration dopamine transporter inhibitor: Alone and in combination with cocaine [abstract 227.10]. Presented at the 35th Annual Meeting of the Society for Neuroscience. Washington, DC; November 12-16, 2005.
37. Peng X-Q, Xi Z-X, Li X, et al.: Methadone pretreatment attenuates heroin's rewarding effects and heroin-induced dopamine release in the nucleus accumbens: Comparison to the effects of CTDP-31,345, a long-lasting dopamine transporter inhibitor [abstract 591.8]. Presented at the 36th Annual Meeting of the Society for Neuroscience. Atlanta, GA; October 14-18, 2006.
38. Brodie JD, Figueroa E,FDewey SL: Treating cocaine addiction: from preclinical to clinical trial experience with gamma-vinyl GABA. Synapse 2003, 50: 261-265.
39. Gerasimov MR, Schiffer WK, Gardner EL, et al.: GABAergic blockade of cocaine-associated cue-induced increases in nucleus accumbens dopamine. Eur J Pharmacol 2001, 414: 205-209.
40. Kushner SA, Dewey SL, Kornetsky C: Gamma-vinyl GABA attenuates cocaine-induced lowering of brain stimulation reward thresholds. Psychopharmacology 1997, 133: 383-388.
41. Xi Z-X, Stein EA: Increased mesolimbic GABA concentration blocks heroin self-administration in the rat. J Pharmacol Exp Ther 2000, 294: 613-619.
42. Kushner SA, Dewey SL, Kornetsky C: The irreversible gamma-aminobutyric acid (GABA) transaminase inhibitor gamma-vinyl-GABA blocks cocaine self-administration in rats. J Pharmacol Exp Ther 1999, 290: 797-802.
43. Peng X-Q, Li X, Gilbert JG, et al.: Gamma-vinyl GABA inhibits cocaine-triggered reinstatement of drug-seeking behavior in rats by a non-dopaminergic mechanism. Drug Alcohol Depend 2007 Dec 4 (Epub ahead of print).
44. Fada P, Scherma M, Fresu A, et al.: Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat. Synapse 2003, 50: 1-6.
45. Slattery DA, Markou A, Froestl W, Cryan JF: The GABAB receptor-positive modulator GS39783 and the GABAB receptor agonist baclofen attenuate the reward-facilitating effects of cocaine: Intracranial self-stimulation studies in the rat. Neuropsychopharmacology 2005, 30: 2065-2072.
46. Roberts DCS: Preclinical evidence for GABAB agonists as a pharmacotherapy for cocaine addiction. Physiol Behav 2005, 86: 18-20.
47. Di Ciano P, Everitt BJ: The GABAB receptor agonist baclofen attenuates cocaine-and heroin-seeking behavior by rats. Neuropsychopharmacology 2003, 28: 510-518.
48. Heidbreder CA, Gardner EL, Xi Z-X, et al.: The role of central dopamine D3 receptors in drug addiction: A review of pharmacological evidence. Brain Res Rev 2005, 49: 77-105.
49. Pak AC, Ashby CR Jr, Heidbreder CA, et al.: The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions. Int J Neuropsychopharmacol 2006, 9: 585-602.
50. Xi Z-X, Gardner EL: Pharmacological actions of NGB 2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction. CNS Drug Rev 2007, 13: 240-259.